Skin puckering and edema during durvalumab therapy.
作者信息
Olamiju Brianna, Odell Ian, Panse Gauri, Eder Joseph P, Leventhal Jonathan S
机构信息
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
出版信息
JAAD Case Rep. 2020 Nov 25;7:110-112. doi: 10.1016/j.jdcr.2020.11.019. eCollection 2021 Jan.
Abstract
摘要
相似文献
1
Skin puckering and edema during durvalumab therapy.度伐利尤单抗治疗期间的皮肤皱缩和水肿。
JAAD Case Rep. 2020 Nov 25;7:110-112. doi: 10.1016/j.jdcr.2020.11.019. eCollection 2021 Jan.
2
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.免疫检查点抑制剂治疗后嗜酸性筋膜炎：四例病例及文献复习。
Oncologist. 2020 Feb;25(2):140-149. doi: 10.1634/theoncologist.2019-0508. Epub 2019 Oct 15.
3
Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced "Eosinophilic Fasciitis-Like" Case and a Review of the Literature.免疫检查点抑制剂相关硬皮病样综合征：一例帕博利珠单抗诱导的“嗜酸性筋膜炎样”病例报告及文献综述
Rheumatol Ther. 2020 Dec;7(4):1045-1052. doi: 10.1007/s40744-020-00246-z. Epub 2020 Oct 16.
4
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.实体癌中免疫检查点抑制剂诱导的免疫性血小板减少症：病例报告与文献综述
Front Oncol. 2020 Dec 7;10:530478. doi: 10.3389/fonc.2020.530478. eCollection 2020.
5
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.程序性死亡配体1抑制剂度伐利尤单抗联合聚（ADP-核糖）聚合酶抑制剂奥拉帕利或血管内皮生长因子受体1-3抑制剂西地尼布在女性癌症中的安全性和临床活性：一项剂量递增的I期研究。
J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.
6
Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment.度伐利尤单抗诱发的新发环状银屑病样药疹经窄谱紫外线B光疗与局部治疗联合成功治愈。
J Dermatol. 2020 Sep;47(9):1041-1045. doi: 10.1111/1346-8138.15371. Epub 2020 Jul 1.
7
Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.多柔比星联合顺铂同期放化疗治疗肺多形性癌的长期疗效：1 例报告。
Thorac Cancer. 2020 Apr;11(4):1090-1093. doi: 10.1111/1759-7714.13331. Epub 2020 Feb 11.
8
Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report.度伐利尤单抗诱导的弥漫性肺泡出血：一例尸检病例报告
Case Rep Oncol. 2020 Jun 22;13(2):696-701. doi: 10.1159/000507848. eCollection 2020 May-Aug.
9
Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.与抗程序性细胞死亡配体-1免疫检查点阻断剂度伐利尤单抗同时进行放疗：一项1/2期试验的单中心亚组分析
Eur J Cancer. 2016 Nov;68:156-162. doi: 10.1016/j.ejca.2016.09.013. Epub 2016 Oct 17.
10
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).一项评估度伐利尤单抗联合曲妥珠单抗治疗 HER2 阳性转移性乳腺癌（CCTG IND.229）的 Ib 期临床试验。
Oncologist. 2019 Nov;24(11):1439-1445. doi: 10.1634/theoncologist.2019-0321. Epub 2019 Aug 16.
本文引用的文献
1
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.免疫检查点抑制剂治疗后嗜酸性筋膜炎：四例病例及文献复习。
Oncologist. 2020 Feb;25(2):140-149. doi: 10.1634/theoncologist.2019-0508. Epub 2019 Oct 15.
2
Eosinophilic fasciitis: Current concepts.嗜酸性筋膜炎：当前概念
Clin Dermatol. 2018 Jul-Aug;36(4):487-497. doi: 10.1016/j.clindermatol.2018.04.006. Epub 2018 Apr 10.
3
Clinicopathologic and immunophenotypic features of eosinophilic fasciitis and morphea profunda: A comparative study of 27 cases.嗜酸粒细胞性筋膜炎和深部硬皮病的临床病理和免疫表型特征：27 例对比研究。
J Am Acad Dermatol. 2018 Jan;78(1):121-128. doi: 10.1016/j.jaad.2017.06.148. Epub 2017 Aug 31.
4
Diagnosis and classification of eosinophilic fasciitis.嗜酸性筋膜炎的诊断和分类。
Autoimmun Rev. 2014 Apr-May;13(4-5):379-82. doi: 10.1016/j.autrev.2014.01.019. Epub 2014 Jan 11.
Zotero 插件